Phenotypes Associated with This Genotype

Genotype
MGI:5521585

• Allelic Composition: Apc^tm2Tno/Apc⁺
• Genetic Background: involves: C57BL/6J

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

digestive/alimentary system

intestine polyps ( J:86036 )

• treatment with pioglitazone or bezafibrate suppresses polyp development

homeostasis/metabolism

increased circulating cholesterol level ( J:86036 )

• total cholesterol levels are increased between 6 and 12 weeks of age

increased circulating free fatty acids level ( J:86036 )

• free fatty acid levels are increased at 12 weeks of age

increased circulating triglyceride level ( J:86036 )

• triglyceride levels are increased after 6 weeks of age, with levels almost 10 times higher at 12 weeks of age than at 6 weeks of age

hyperlipidemia ( J:86036 )

• seen with age

• treatment with pioglitazone or bezafibrate decreases serum lipid levels and reduces severity of hepatic steatosis

liver/biliary system

hepatic steatosis ( J:86036 )

• centrilobular-restricted steatosis is seen in the livers of all mutants at 12 weeks of age, with numerous microvesicular fatty droplets in the cytoplasm of parenchymal cells

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
familial adenomatous polyposis		DOID:0050424	OMIM:PS175100	J:86036